In our study, we found the same confirmation of low THBS1 expression in the bone marrow of AML patients, and this result was validated by previous studies where THBS1 expression was significantly lower, but methylation was higher in AML patients, and methylation of the THBS1 gene was associated with AML and prognosis, while hypomethylating agent treatment resulted in upregulation of THBS1 expression and lower methylation levels (Zhu et al., 2019). The gene discussed is THBS1; the disease is acute myeloid leukemia.